NewWhen should migraine prevention be offered? New US guideline
The American Academy of Neurology and the American Headache Society updated their guideline on preventive medicines for migraine in adults, the first update since 2012.
- What changed
- Prevention should be offered to people with four or more migraine days a month, four or more moderate-to-severe headache days a month, or migraine that gets in the way of work and daily life.
- Newer medicines, the CGRP antibodies given by injection monthly or every three months and atogepant taken by mouth, now sit alongside older medicines among the options with high or moderate confidence in the evidence.
- A medicine should be judged after 8 to 12 weeks at the right dose; Botox for chronic migraine after 24 weeks.
- For anyone who could become pregnant: valproate and topiramate should be avoided where possible because of the risk to a baby. Topiramate above 200 mg a day can make hormonal contraception less reliable.
- What this means for you
- If your attacks are frequent or disrupt your days, prevention is worth asking about.
- If one medicine doesn’t work, a different type may.
- Give a medicine two to three months before judging it, unless the side effects are troublesome.
- What it doesn’t mean
- It doesn’t mean the newer medicines suit everyone, or that you should stop one that works for you.
- This is a US guideline; which medicines are available and covered differs between countries.
Read also: Migraine and attack triggers
Source: Potrebic S, Tanveer S, Becker WJ, et al. Pharmacologic treatment for migraine prevention in adults: practice guideline recommendations. Neurology 2026;107(7):e214881. doi.org/10.1212/WNL.0000000000214881